Table 1 Demographics and baseline disease characteristicsa.
Ofatumumab (n = 240) | Observation (n = 240) | |
|---|---|---|
Age, yearsb | ||
Median (min–max) | 64.0 (33–86) | 64.5 (39–87) |
<70, n (%) | 167 (70) | 166 (69) |
≥70, n (%) | 73 (30) | 74 (31) |
≥75, n (%) | 42 (18) | 35 (15) |
Sex, n (%) | ||
Female | 79 (33) | 80 (33) |
Male | 161 (67) | 160 (67) |
Time since diagnosis, median (range) in year | 6.0 (1–22) | 5.0 (1–22) |
Response to last CLL treatment, n (%) | ||
CR | 47 (20) | 47 (20) |
PR | 193 (80) | 192 (80) |
Missing | 0 | 1 (<1) |
Baseline MRD, n (%) | ||
Negative | 31 (13) | 42 (18) |
Positive | 139 (58) | 107 (45) |
Missing | 70 (29) | 91 (38) |
No. of prior treatments, n (%) | ||
2 | 169 (70) | 168 (70) |
3 | 67 (28) | 63 (26) |
Other | 4 (2) | 9 (4) |
Type of last prior treatment, n (%) | ||
Chemoimmunotherapy | 193 (80) | 193 (80) |
BR | 46 (24) | 48 (25) |
FCR | 100 (52) | 105 (54) |
FR | 4 (2) | 5 (3) |
Other | 30 (16) | 24 (12) |
RCVP | 13 (7) | 11 (6) |
Alkylating monotherapy | 14 (6) | 9 (4) |
Other | 33 (14) | 38 (16) |
Baseline cytogenetics, n (%)c | ||
11q deletion | 15 (6) | 13 (5) |
17p deletion | 7 (3) | 4 (2) |
6q deletion or 12q trisomy or 13q deletion | 47 (20) | 16 (7) |
No aberration | 151 (63) | 174 (73) |
Missing | 20 (8) | 33 (14) |
IGVH mutational status, n (%) | ||
Mutated | 54 (23) | 74 (31) |
Unmutated | 139 (58) | 116 (48) |
Not available | 3 (1) | 1 (<1) |
Missing | 44 (18) | 49 (20) |
